SteelPeak Wealth’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$258K Sell
5,376
-277
-5% -$11.9K 0.01% 565
2026
Q1
$215K Sell
5,653
-1,537
-21% -$72.8K 0.01% 518
2025
Q4
$366K Buy
7,190
+1,860
+35% +$95.1K 0.01% 398
2025
Q3
$296K Sell
5,330
-2,175
-29% -$127K 0.01% 470
2025
Q2
$518K Sell
7,505
-704
-9% -$47.9K 0.02% 358
2025
Q1
$578K Buy
8,209
+408
+5% +$33.7K 0.02% 324
2024
Q4
$671K Buy
7,801
+3,220
+70% +$348K 0.03% 300
2024
Q3
$545K Buy
4,581
+84
+2% +$11.2K 0.02% 303
2024
Q2
$642K Sell
4,497
-419
-9% -$55.5K 0.03% 281
2024
Q1
$636K Buy
4,916
+690
+16% +$82.1K 0.03% 270
2023
Q4
$437K Sell
4,226
-500
-11% -$49.4K 0.03% 295
2023
Q3
$430K Buy
4,726
+50
+1% +$4.41K 0.03% 274
2023
Q2
$378K Buy
4,676
+1,002
+27% +$81.9K 0.02% 289
2023
Q1
$295K Hold
3,674
0.02% 306
2022
Q4
$249K Buy
+3,674
New +$215K 0.02% 334
2022
Q3
Sell
-4,302
Closed -$240K 428
2022
Q2
$240K Hold
4,302
0.02% 355
2022
Q1
$239K Buy
4,302
+246
+6% +$12.6K 0.01% 376
2021
Q4
$227K Buy
+4,056
New +$220K 0.01% 369

Other funds holding NVO

SteelPeak Wealth's NVO Position: Q2 2026 in Review

SteelPeak Wealth reduced its Novo Nordisk (NVO) stake by 4.9% in Q2 2026, selling an estimated $11.9K and leaving 5,376 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #565.

SteelPeak Wealth first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $671K in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • SteelPeak Wealth held 5,376 shares of Novo Nordisk worth $258K as of Q2 2026.
  • SteelPeak Wealth sold 277 Novo Nordisk shares in Q2 2026, an estimated $11.9K.
  • Novo Nordisk made up 0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #565 holding.
  • SteelPeak Wealth first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
  • SteelPeak Wealth's Novo Nordisk position peaked at $671K in Q4 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.